Biofrontera

Biofrontera R&D per Employee

The R&D Spending per Employee of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 14,400.00 EUR. In the previous year, R&D Spending per Employee was 14,180.65 EUR — a change of 1.55% (higher).

R&D per Employee

14,400.00EUR

YoY

1.55%

Last updated:

R&D Spending per Employee of Biofrontera is 2025 14,400.00 EUR. R&D Spending per Employee of Biofrontera was 2024 14,180.65 EUR. It decreases by 1.55% higher compared to the previous year.

The Biofrontera R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
28,561.29 EUR
Jan 1, 2019
29,909.68 EUR
Jan 1, 2020
30,896.77 EUR
Jan 1, 2021
45,219.35 EUR
Jan 1, 2022
45,987.10 EUR
Jan 1, 2023
50,619.35 EUR
Jan 1, 2024
14,180.65 EUR
Jan 1, 2025
14,400.00 EUR
The Biofrontera R&D per Employee history
YEARR&D per EmployeeYoY
14,400.00EUR+1.55%
14,180.65EUR-71.99%
50,619.35EUR+10.07%
45,987.10EUR+1.70%
45,219.35EUR+46.36%
30,896.77EUR+3.30%
29,909.68EUR+4.72%
28,561.29EUR+4.78%
27,258.06EUR-8.95%
29,937.57EUR-25.20%
40,025.72EUR+36.83%
29,252.78EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

R&D Spending per Employee of Biofrontera is 14,400.00 EUR in 2025.

R&D Spending per Employee of Biofrontera changed from 14,180.65 EUR to 14,400.00 EUR, representing a 1.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Biofrontera since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Biofrontera

All Key Metrics — Biofrontera